A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Am J Clin Oncol
; 21(4): 406-7, 1998 Aug.
Article
en En
| MEDLINE
| ID: mdl-9708643
ABSTRACT
Twenty-nine evaluable patients with endometrial cancer were treated with amonafide 300 mg/m2 for 5 consecutive days every 3 weeks. Two partial responses (8%) were seen. Hematologic toxicity was severe or life-threatening in 13 patients occurring as follows leukopenia in 13 patients (45%); thrombocytopenia in 10 patients (34%); granulocytopenia in 13 patients (45%); and anemia in four patients (14%). In view of the low response rate and high toxicity, this dose schedule of amonafide does not warrant further investigation in endometrial cancer.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Endometriales
/
Imidas
/
Isoquinolinas
/
Antineoplásicos
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Am J Clin Oncol
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos